Interleukin-1 production by mononuclear cells from patients with scleroderma

Area of Science:

• Immunology
• Rheumatology

Background:

• Scleroderma, or progressive systemic sclerosis (PSS), is an autoimmune disease characterized by fibrosis and vascular abnormalities.
• Interleukin-1 (IL-1) is a key cytokine involved in inflammation and immune responses.

Purpose of the Study:

• To investigate Interleukin-1 (IL-1) production by peripheral blood mononuclear cells (PBMC) in patients with scleroderma.
• To explore potential regulatory mechanisms of IL-1 activity in progressive systemic sclerosis (PSS).

Main Methods:

• Peripheral blood mononuclear cells (PBMC) were isolated from patients with PSS and healthy controls.
• IL-1 activity was measured using thymocyte proliferation assays.
• PBMC cultures were performed at different cell densities (10^5 cells/ml and 10^6 cells/ml).
• Supernatants were analyzed undiluted and after dilution, with and without indomethacin.

Main Results:

• Unstimulated PBMC from 10 of 13 PSS patients exhibited significantly lower IL-1 activity compared to controls.
• IL-1 activity per monocyte/macrophage was 10-fold higher at lower cell densities (10^5 cells/ml).
• Dilution of supernatants and addition of indomethacin increased IL-1 activity, particularly in undiluted samples.

Conclusions:

• Crude PBMC supernatants from PSS patients show low IL-1 activity.
• IL-1 activity in PSS may be regulated by non-dialyzable inhibitors produced by PBMC.
• Cell interactions and inhibitory factors likely play a role in modulating IL-1 levels in scleroderma.